Brokerages Set COMPASS Pathways plc (NASDAQ:CMPS) Price Target at $33.60

COMPASS Pathways plc (NASDAQ:CMPS) has been given a consensus rating of “Buy” by the six research firms that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $33.60.

A number of brokerages have issued reports on CMPS. Maxim Group cut their price target on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 1st. HC Wainwright cut their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $18.00 target price on shares of COMPASS Pathways in a research note on Wednesday, January 15th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new stake in shares of COMPASS Pathways in the fourth quarter worth about $41,000. Wealthfront Advisers LLC purchased a new position in COMPASS Pathways during the 4th quarter valued at approximately $43,000. Flagship Harbor Advisors LLC bought a new stake in COMPASS Pathways in the 4th quarter worth approximately $43,000. Conservest Capital Advisors Inc. raised its holdings in shares of COMPASS Pathways by 28.9% during the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock worth $51,000 after acquiring an additional 3,000 shares in the last quarter. Finally, Simplify Asset Management Inc. bought a new position in shares of COMPASS Pathways during the 4th quarter valued at approximately $54,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Stock Performance

Shares of NASDAQ CMPS opened at $4.25 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a 1 year low of $3.16 and a 1 year high of $12.75. The firm has a fifty day moving average price of $4.09 and a 200-day moving average price of $5.50. The stock has a market cap of $290.79 million, a PE ratio of -1.93 and a beta of 2.28.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.